Kymera Therapeutics (KYMR) Capital Leases (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Capital Leases of $1.2 million for Q1 2026, down 39.68% year-over-year from $1.9 million in Q1 2025, and down 21.27% quarter-over-quarter from $1.5 million in Q4 2025.
Kymera Therapeutics (KYMR) Capital Leases (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Capital Leases for 8 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Leases fell 39.68% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 39.68% YoY), while the FY2025 annual figure was $1.5 million, down 34.32% from the prior year.
- Capital Leases retreated to $1.2 million in Q1 2026 per KYMR's latest filing, from $1.5 million in the prior quarter.
- Across five years, Capital Leases topped out at $2.2 million in Q4 2024 and bottomed at $643000.0 in Q3 2023.
- Historically, Capital Leases has averaged $1.3 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Capital Leases slumped 48.78% — and 2024, when it soared 171.23%.
- Kymera Therapeutics' Capital Leases stood at $1.2 million in 2022, then climbed by 4.41% to $1.3 million in 2023, then surged by 71.1% to $2.2 million in 2024, then plunged by 34.32% to $1.5 million in 2025, then dropped by 21.27% to $1.2 million in 2026.
- Business Quant data shows KYMR's Capital Leases at $1.2 million in Q1 2026, $1.5 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 840,000.00 |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 2.23 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 943,000.00 |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 643,000.00 |
| Jun 30, 2023 | 762,000.00 |
| Mar 31, 2023 | 989,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 690,000.00 |
| Jun 30, 2022 | 927,000.00 |
| Mar 31, 2022 | 927,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.35 Mn |